Phase 4 N=30 Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor
Pelvic Organ Prolapse · Menopause
Primary: Vaginal Wall Composition: Epithelium (Intention to Treat) — 413.9; 314.1 microns — p=0.21
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=55 Trial of D-Cycloserine in Schizophrenia
Schizophrenia
Primary: Scale for the Assessment of Negative Symptoms (SANS) — -.46; -.41 units on a scale/weeks
Phase 2 N=74 Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Combination Therapy With VELCADE, Dexamethasone, and Doxil, (RVDD) — 25; 1.3; 20; 30 mg
Phase 4 N=21 An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers
Hepatic Impairment
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 49.00; 36.26; 35.94; 69.03 ug/mL
Phase 3 N=200 Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Anemia · Traumatic Brain Injury
Primary: Glasgow Outcome Scale — 17; 17; 34; 37 participants — p=.01
Phase 3 N=192 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12 — 24.62; 25.12; -10.03; -9.18 mmHg
Early Phase 1 N=64 Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein
ADD · ADHD
Primary: Reaction Time at 3 Months — 506.58; 510.59 milliseconds — p=0.56593
Phase 2 N=314 Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
Joint Damage
Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472
Phase 2 N=122 Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Hepatitis C
Primary: Segment 1: Safety — 93.3; 100.0; 93.8; 100.0 percentage of participants
N/A N=1,372 MDs on Botox Utility (MOBILITY)
Blepharospasm · Torticollis · Strabismus
Primary: Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Cervical Dystonia — 0.650; 0.676…
Phase 3 N=22 Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period — 2.1; 2.5; 27.5; 30.3 mg/kg/day
Phase 1 N=64 A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
Angina Pectoris · Coronary Heart Disease · Calcitonin Gene-related Peptide Receptor
Primary: Number of Participants With Clinical Adverse Events (AEs) — 7; 1; 5 Participants
N/A N=8 An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients
Donor Site Complication
Primary: Percentage of Participants Who Had > 95 % Epithelialization at Day 10 — 0 percentage of participants
N/A N=1,223 Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients
Critical Illness · Sepsis · Multiple Organ Failure
Primary: 28-day Mortality — 97; 89; 101; 76 participants
Phase 3 N=24 Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
Alpha 1-Antitrypsin Deficiency
Primary: Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7 — 155.9; 152.4 mg*h/mL